Covalab invests more than €1 million in bioproduction operations for antibodies for Covid-19 diagnostics
- Company’s BioDiaThera project received almost €500,000 in subsidies as part of French ‘Capacity Building’ scheme
- Covalab plans to develop production platform for recombinant proteins and antibodies for use in diagnostic tests for Covid-19, developed using French technologies and expertis
PRESS Release
